Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Atea Pharmaceuticals: The U.S. FDA Granted Fast Track Designation to Bemnifosbuvir Oral Antiviral for COVID-19

April 25, 2023 0

Atea Pharmaceuticals Receives Fast Track Designation for Bemnifosbuvir Atea Pharmaceuticals (AVIR) announced that the U.S. FDA …

Apellis Pharmaceuticals: Validation of 4 Marketing Applications for Pegcetacoplan for Geographic Atrophy

April 21, 2023 0

Apellis Pharmaceuticals Validation for Pegcetacoplan Apellis Pharmaceuticals (APLS) announced the receival of validation of its marketing applications …

CymaBay Therapeutics: Results From Phase 3 Study of Seladelpar in Patients with PBC Published in Hepatology

April 21, 2023 0

Important News from CymaBay Therapeutics Primary Biliary Cholangitis Today, April 21, 2023, CymaBay Therapeutics (CBAY) announced that …

Important News from Novartis MS Product Kesimpta®

April 20, 2023 0

From Novartis on April 20, 2023 The ALITHIOS open-label extension study demonstrated that continuous treatment with …

Innoviva: The FDA Advisory Committee Unanimously Recommended Approval of Sulbactam-Durlobactam

April 19, 2023 0

News from Innoviva That We Consider Positively Impacting and Extremely Important Innoviva, Inc. (INVA) (Innoviva), announced …

Why the FDA Accepted to Review Merck’s KEYTRUDA (sBLA) for The Treatment of HER2 Negative Gastric Adenocarcinoma

April 14, 2023 0

Merck in the NEWS Merck (MRK) announced that the U.S. FDA has accepted for review a …

Sanofi to Reach Full Commercial Control of the Antibody Beyfortus (nirsevimab) against RSV in the U.S.

April 12, 2023 0

Sanofi Commercial Control of Beyfortus Against RSV In the morning, we promised to tell our readers …

Regenxbio Receives FDA Fast Track Designation for RGX-202 for the Treatment of Duchenne Muscular Dystrophy

April 11, 2023 0

Regenxbio in the NEWS Today, the U.S. FDA granted Fast Track designation for Regenxbio (RGNX) Gene therapy …

Vertex and CRISPR Complete Submission of BLAs to the US FDA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

April 3, 2023 0

Vertex Pharmaceuticals and CRISPR Therapeutics Completion of BLAs Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) announced …

TG Therapeutics Announced Positive CHMP Opinion of BRIUMVI for Relapsing Forms of MS in Adults

April 3, 2023 0

TG Therapeutics Positive CHMP of BRIUMVI TG Therapeutics, Inc. (TGTX), informed that the Committee for Medicinal …

New Study from Neuvivo’s NP001: First to Link Regulation of the Innate Immune System with Respiratory Function in ALS

March 31, 2023 0

New Study from Neuvivo On March 30, 2023, Neuvivo – a private Company, announced the publication of …

The EU CHMP Agency Recommended Approval of TG Therapeutics Firm’s BRIUMVI™ for Relapsing Forms of MS in Adults

March 31, 2023 0

TG Therapeutics TG Therapeutics, Inc. (TGTX) announced today that the Committee for Medicinal Products for Human …

The U.S. FDA Accepted Checkpoint Therapeutics Biotech BLA for Cosibelimab

March 31, 2023 0

Checkpoint Therapeutics Checkpoint Therapeutics (CKPT) is a clinical-stage immunotherapy and targeted oncology company focused on the …

BrainStorm Cell Therapeutics: Another Clinical-Stage Small Firm’s Product for the Devastating Disease ALS

March 27, 2023 0

BrainStorm Cell Therapeutics Inc BrainStorm Cell Therapeutics Inc (BCLI) develops innovative autologous adult stem cell therapeutics …

An Important New Licensing Agreement Between Vertex Pharmaceuticals and CRISPR Therapeutics

March 27, 2023 0

Vertex Pharmaceuticals and Crispr Therapeutics Agreement Aims at Accelerating Vertex's Hypo immune Cell Therapies for Type …

Vertex Pharmaceuticals Recent Impacting News

March 24, 2023 0

Important News from Vertex Vertex Pharmaceuticals (VRTX) is a worldwide biotechnology company that invests in scientific …

23andMe Teams Up with Novartis on Lipoprotein(a) Education for its Customers

March 24, 2023 0

23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease March …

CymaBay Therapeutics’ Clinical Trials Brought Proof of Concept of its Technology and More

March 21, 2023 0

CymaBay Therapeutics CymaBay Therapeutics (CBAY) is a clinical-stage biopharmaceutical firm focused on improving the lives of people …

As Expected, Seagen Was Taken Over, the Buyer is Pfizer.

March 13, 2023 0

Pfizer to Acquire Seagen Pfizer (PFE) is to acquire Seagen (SGEN) for $229 per share in …

What We Are Looking for in a Bear Market

March 11, 2023 0

The Stock Market The volatility continues in the Bear market with investors not knowing what to …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Atea Pharmaceuticals: The U.S. FDA Granted Fast Track Designation to Bemnifosbuvir Oral Antiviral for COVID-19

Apellis Pharmaceuticals: Validation of 4 Marketing Applications for Pegcetacoplan for Geographic Atrophy

CymaBay Therapeutics: Results From Phase 3 Study of Seladelpar in Patients with PBC Published in Hepatology

Important News from Novartis MS Product Kesimpta®

Innoviva: The FDA Advisory Committee Unanimously Recommended Approval of Sulbactam-Durlobactam

Why the FDA Accepted to Review Merck’s KEYTRUDA (sBLA) for The Treatment of HER2 Negative Gastric Adenocarcinoma

Sanofi to Reach Full Commercial Control of the Antibody Beyfortus (nirsevimab) against RSV in the U.S.

Regenxbio Receives FDA Fast Track Designation for RGX-202 for the Treatment of Duchenne Muscular Dystrophy

Vertex and CRISPR Complete Submission of BLAs to the US FDA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

TG Therapeutics Announced Positive CHMP Opinion of BRIUMVI for Relapsing Forms of MS in Adults

New Study from Neuvivo’s NP001: First to Link Regulation of the Innate Immune System with Respiratory Function in ALS

The EU CHMP Agency Recommended Approval of TG Therapeutics Firm’s BRIUMVI™ for Relapsing Forms of MS in Adults

The U.S. FDA Accepted Checkpoint Therapeutics Biotech BLA for Cosibelimab

BrainStorm Cell Therapeutics: Another Clinical-Stage Small Firm’s Product for the Devastating Disease ALS

An Important New Licensing Agreement Between Vertex Pharmaceuticals and CRISPR Therapeutics

Vertex Pharmaceuticals Recent Impacting News

23andMe Teams Up with Novartis on Lipoprotein(a) Education for its Customers

CymaBay Therapeutics’ Clinical Trials Brought Proof of Concept of its Technology and More

As Expected, Seagen Was Taken Over, the Buyer is Pfizer.

What We Are Looking for in a Bear Market